Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs (TREV)

The Usefulness of Circulating Microvesicles (host and Bacterial) in Regulating Metabolic Homeostasis in Obesity Randomized Study of Parallel Arms in Obese Patients Undergoing Caloric Restriction Diet Vs. Early Time-restricted Eating

The main aim of the present study is to evaluate the effectiveness of two dietary protocols: Daily Caloric Restriction (DCR) and Early Time-Restricted Feeding + DCR (eTRE) on metabolic homeostasis and the influence of circulating extracellular vesicles (EVs) as inter-organ communication elements in obese patients.

Study Overview

Detailed Description

The specific objectives are:

  1. To assess the effect of two dietary protocols on weight loss and metabolic benefits in non-morbidly obese subjects.
  2. Influence of both protocols on energy signaling metabolites and the dynamics of enteroendocrine hormones.
  3. Define the "digital footprint" of EVs as inter-organ communication elements influencing metabolic status in obese subjects.

The study design comprises a randomized parallel-arm design (n=40) with consecutive 1:1 allocation to a calorie restriction protocol for a healthy Mediterranean diet under Daily Caloric Restriction (DCR) (n=20) or an eTRE protocol (n=20) for 12 weeks. Clinical and analytical variables, adherence, satiety, chronotype, and brown fat content will be determined before and at the end of the follow-up. Derivatives of intestinal microbiota, short-chain fatty acids, bile acids, and circulating metabolites derived from host intermediary metabolism will be assessed through metabolomics. Glucagon-like peptide 1 (GLP1) and gastric inhibitory polypeptide (GIP) dynamics after a standard meal test. Metagenomics. Bioenergetic analysis of PBMC by SeaHorse. Total EV miRNA profile. Isolation of host and bacterial EVs. Characterization of the protein cargo of host and bacterial EVs.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tarragona, Spain, 43005
        • Recruiting
        • Hospital Universitario de Tarragona Juan XXIII
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. age between 18 and 70 years old.
  2. BMI ranges between 27 and 40 kg/ m2.
  3. Absence of underlying pathology in medical and physical examination, except for those related to excess weight.
  4. Signature of the informed consent for participation in the study.

Exclusion Criteria:

  1. Serious systemic disease not related to obesity, such as cancer, kidney or severe liver disease.
  2. Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as rheumatoid arthritis and asthma).
  3. Pregnancy and lactation.
  4. Vegetarians or subjects subjected to an irregular diet.
  5. Patients with severe eating disorders.
  6. Patients with clinical symptoms and signs of infection in the previous month.
  7. Patients with chronic anti-inflammatory steroid treatments and/or nonsteroidal anti-inflammatory drugs.
  8. Recent antibiotic treatment.
  9. Uncontrolled alcoholism or drug abuse.
  10. Rotating or nocturnal shift workers.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Continuous caloric restriction
Continuous calorie restriction diet based on healthy Mediterranean diet recommendations
Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
Experimental: eTRE
early (morning) time-restricted eating (eTRE) plus continuous caloric restriction diet based on healthy Mediterranean diet recommendations
early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Anthropometric measurements (I)
Time Frame: Before and after (12 weeks) of the intervention
Changes in weight (kg)
Before and after (12 weeks) of the intervention
Anthropometric measurements (II)
Time Frame: Before and after (12 weeks) of the intervention
Changes in body mass index (kg/m^2);
Before and after (12 weeks) of the intervention
Anthropometric measurements (III)
Time Frame: Before and after (12 weeks) of the intervention
Changes waist circumference (cm)
Before and after (12 weeks) of the intervention
Anthropometric measurements (IV)
Time Frame: Before and after (12 weeks) of the intervention
Changes hip circumference (cm)
Before and after (12 weeks) of the intervention
Anthropometric measurements (V)
Time Frame: Before and after (12 weeks) of the intervention
Changes neck circumference (cm)
Before and after (12 weeks) of the intervention
Body composition (I)
Time Frame: Before and after (12 weeks) of the intervention
Changes in fat body mass (kg); assesed by bioimpedance monitoring device (Seca®)
Before and after (12 weeks) of the intervention
Body composition (II)
Time Frame: Before and after (12 weeks) of the intervention
Changes in lean body mass (kg); assesed by bioimpedance monitoring device (Seca®)
Before and after (12 weeks) of the intervention
Body composition (III)
Time Frame: Before and after (12 weeks) of the intervention
Changes visceral adipose tissue (L); assesed by bioimpedance monitoring device (Seca®)
Before and after (12 weeks) of the intervention
Brown fat
Time Frame: Before and after (12 weeks) of the intervention
Changes in brown fat volume (cm3); assessed by magnetic resonance image (MRI)
Before and after (12 weeks) of the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gut and host microbiota-derived metabolites (I)
Time Frame: Before and after (12 weeks) of the intervention
Changes in circulating short-chain fatty acids levels [µM]; assesed by Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS)
Before and after (12 weeks) of the intervention
Gut and host microbiota-derived metabolites (II)
Time Frame: Before and after (12 weeks) of the intervention
Changes in circulating bile acids levels [nM]; Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Before and after (12 weeks) of the intervention
Gut and host microbiota-derived metabolites (III)
Time Frame: Before and after (12 weeks) of the intervention
Changes in circulating succinate levels [µM]; assesed by EnzyChrom™ Succinate Assay Kit
Before and after (12 weeks) of the intervention
Entero-endocrine incretin hormones (I)
Time Frame: Before and after (12 weeks) of the intervention
Changes in post-prandial response to a meal-tolerance test in serum levels of glucose [mg/dL]; assesed by ELISA kit
Before and after (12 weeks) of the intervention
Entero-endocrine incretin hormones (II)
Time Frame: Before and after (12 weeks) of the intervention
Changes in post-prandial response to a meal-tolerance test in serum levels of insulin levels [pmol/L] ]assesed by ELISA kit
Before and after (12 weeks) of the intervention
Entero-endocrine incretin hormones (III)
Time Frame: Before and after (12 weeks) of the intervention
Changes in post-prandial response to a meal-tolerance test in plasma levels of glucagon-like peptite 1 [GLP-1 ] (pmol/L); assesed by ELISA kit
Before and after (12 weeks) of the intervention
Entero-endocrine incretin hormones (IV)
Time Frame: Before and after (12 weeks) of the intervention
Changes in post-prandial response to a meal-tolerance test in plasma levels of gastric inhibitory polypeptide (GIP) [pg/mL]; assesed by ELISA kit
Before and after (12 weeks) of the intervention
Microbial composition/metagenomic
Time Frame: Before and after (12 weeks) of the intervention
Changes in alpha and beta diversity, relative abundance and functional metagenomics; assesed by Ilumina metagenomics
Before and after (12 weeks) of the intervention
Cellular energy metabolism
Time Frame: Before and after (12 weeks) of the intervention
Changes in Cluster of Differentiation 14 positive (CD14+) monocytes isolated from peripheral blood mononuclear cells (PBMCs) will be used for bioenergetics analysis via an extracellular flux analyzer
Before and after (12 weeks) of the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Juan José Vendrell Ortega, Professor, Instituto de Investigación Sanitaria Pere Virgili (IISPV)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 20, 2024

Primary Completion (Estimated)

May 30, 2025

Study Completion (Estimated)

December 20, 2025

Study Registration Dates

First Submitted

April 24, 2024

First Submitted That Met QC Criteria

April 29, 2024

First Posted (Actual)

May 2, 2024

Study Record Updates

Last Update Posted (Actual)

October 4, 2024

Last Update Submitted That Met QC Criteria

October 3, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe